Asked by: Virendra Sharma (Labour - Ealing, Southall)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, whether she plans to include additional material on heart valve disease in the Major Conditions Strategy.
Answered by Andrew Stephenson - Minister of State (Department of Health and Social Care)
In the development of the Major Conditions Strategy, we are committed to focusing on the six major groups of conditions, which includes cardiovascular disease. Aligning work across several groups of conditions allows us to focus on where there are similarities in approach to ensure care is better centred around the patient, health and care resources are used most effectively, and that there is effective integration, both within and between treatment pathways.
This strategy does not seek to describe everything that is being done or could be done to meet the challenges of specific diseases within the major conditions. Instead, we are focusing on developing a strategic approach to inform the wide range of decisions health and care organisations make when determining how best to care for the people they serve.
Asked by: Virendra Sharma (Labour - Ealing, Southall)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, whether she has made an estimate of the number of heart valve disease patients treated in non-elective settings in the last 12 months; and whether she has made an assessment of the potential impact of this treatment on (a) hospital capacity and (b) patient's quality of life.
Answered by Andrew Stephenson - Minister of State (Department of Health and Social Care)
NHS England’s Hospital Episode Statistics tell us that there were 11,581 non-elective hospital admissions for heart valve disease in 2022/23. There has been no specific assessment made of the potential impact of this treatment on hospital capacity or on patients quality of life. The National Health Service will, at all times, aim to provide patients with the care which responds to their needs. This includes patients who are admitted to hospital through non-elective routes for heart valve disease.
The NHS is also taking action to identify cardiovascular disease before a patient is admitted to hospital. The NHS has rolled out free blood pressure checks to people over the age of 40 in community pharmacies to detect thousands more people living with hypertension earlier. This means more people can access simple, low-cost treatments that will reduce their risk of death or serious illness from cardiovascular disease. Furthermore, 108 community diagnostic centres have opened that have delivered more than 3.9 million tests, including those that detect cardiovascular disease.
NHS England has included hypertension case-finding, optimal management, and lipid optimal management as one of its five clinical areas of focus requiring accelerated improvement within the Core20PLUS5 approach. The Core20PLUS5 informs action to reduce healthcare inequalities at both national and system level.
Asked by: Virendra Sharma (Labour - Ealing, Southall)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what steps her Department is taking to tackle disparities in access to medical treatment for heart valve disease.
Answered by Andrew Stephenson - Minister of State (Department of Health and Social Care)
In the development of the Major Conditions Strategy, we are committed to focusing on the six major groups, which includes cardiovascular disease. As part of the policy development process, the Major Conditions Strategy will consider the full range of health disparities that may be experienced by different groups, including ethnic and gender disparities.
Asked by: Virendra Sharma (Labour - Ealing, Southall)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, whether she has made an assessment of the potential merits of (a) active and (b) passive surveillance measures in informing prevention strategies for infectious diseases in newborn babies.
Answered by Maria Caulfield - Parliamentary Under Secretary of State (Department for Business and Trade) (Minister for Women)
The Infectious Diseases in Pregnancy Screening programme (IDPS) for HIV, Hepatitis B and syphilis is monitored through surveillance systems within the UK Health Security Agency. This programme is delivered through NHS England which also monitors it through their Integrated Screening Outcomes Surveillance Service (ISOSS). IDPS is offered in every pregnancy, with a high uptake of 99.7%.
All pregnancies with a screen positive result for these infections are reported to NHS England’s ISOSS which conducts active surveillance, including pregnancy and infant outcome. Data collected through ISOSS enables the IDPS to monitor performance, review all positive cases and identify new areas for further audit and research.
All instances of vertical transmission, previously known as mother-to-child transmission, of infection for HIV, hepatitis B and diagnosis of congenital syphilis in babies are investigated and anonymously reviewed by clinical experts to add to the understanding of the burden of disease and risk factors associated with it. Data and findings from ISOSS are used to improve the screening pathway and feed into the production of national clinical guidance for the treatment and management of these infections in pregnancy.
Asked by: Virendra Sharma (Labour - Ealing, Southall)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, whether her Department has made an estimate of the annual economic costs to the NHS of Group B streptococcus infections in newborns.
Answered by Maria Caulfield - Parliamentary Under Secretary of State (Department for Business and Trade) (Minister for Women)
No specific assessment has been made.
Asked by: Virendra Sharma (Labour - Ealing, Southall)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, whether her Department has made a recent assessment of the adequacy of reporting the incidence of Group B streptococcal infections in newborns.
Answered by Maria Caulfield - Parliamentary Under Secretary of State (Department for Business and Trade) (Minister for Women)
No specific assessment has been made.
Asked by: Virendra Sharma (Labour - Ealing, Southall)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, whether she has made an assessment with NHS England of the potential merits of left ventricular assist devices as long-term therapy for patients ineligible for transplantation.
Answered by Andrew Stephenson - Minister of State (Department of Health and Social Care)
NHS England has a commissioning specification for using ventricular assist devices (VADs) as a bridge to transplantation, or as a bridge to a decision on transplant suitability. The use of VADs as a treatment and destination therapy for patients who are not eligible for a transplant, is not routinely commissioned. NHS England has recently received a policy proposition for use of VADs as long-term destination therapy for selected patients with advanced heart failure. This proposition is currently under evaluation in line with the published Policy Methods Process, which is available at the following link:
https://www.england.nhs.uk/publication/methods-national-clinical-policies/
Asked by: Virendra Sharma (Labour - Ealing, Southall)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, how many patients are on the waiting list for an echocardiogram.
Answered by Andrew Stephenson - Minister of State (Department of Health and Social Care)
Data on patients waiting for the test “Cardiology – Echocardiography” is publicly available in the DM01 Data set, which can be found in at the following link:
Asked by: Virendra Sharma (Labour - Ealing, Southall)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, how many times a year NHS England’s Clinical Priorities Advisory Group prioritisation meetings take place; and what the dates are for each meeting in 2024.
Answered by Andrew Stephenson - Minister of State (Department of Health and Social Care)
Clinical Priorities Advisory Group prioritisation meetings are held once per year. NHS England aims to hold the next prioritisation meeting on either 20 or 21 of May 2024.
Asked by: Virendra Sharma (Labour - Ealing, Southall)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what the (a) terms of reference, (b) objectives and (c) deliverable measures are for NHS England’s Device Steering Group for the next 12 months.
Answered by Andrew Stephenson - Minister of State (Department of Health and Social Care)
The steering group will be chaired by the High-Cost Devices Senior Responsible Owner within the NHS England Pricing and Costing team. To maintain the high-cost devices exclusions list, the Pricing and Costing team obtain advice and recommendations from experts working in the relevant fields. The members of this steering group will work in healthcare or pharmaceutical capacities, independent of any private enterprise or commerce, and will be from the Department, National Health Service commissioning, specialist units of the NHS England Pricing team, and the NHS Classifications Service and National Casemix Office of NHS Digital.
There are currently 28 members, of whom, 14 members are from NHS England, nine from providers, four from representative bodies, and one from a commissioner. We are withholding the individual names and job titles of non-senior NHS England staff members, as well as names and job titles for external members of staff.
The steering group provides an independent review of candidate devices, by assessing their suitability for inclusion on the high-cost devices exclusions list, based on pre-existing acceptance criteria. A copy of the nomination form for the addition or removal of a drug or device to be excluded from NHS Payment Scheme prices, is attached for your information.